Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to Onchocerca volvulus in Mice and Non-Human Primates-Reference-Cited by-同舟云学术

Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to Onchocerca volvulus in Mice and Non-Human Primates

Published:2023-07-06 Issue:7 Volume:11 Page:1212
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Ryan Nathan M.¹^ORCID,Hess Jessica A.¹,Robertson Erica J.¹,Tricoche Nancy²,Turner Cheri³,Davis Jenn³,Petrovsky Nikolai⁴^ORCID,Ferguson Melissa⁵,Rinaldi William J.⁵,Wong Valerie M.⁶,Shimada Ayako⁷^ORCID,Zhan Bin⁸^ORCID,Bottazzi Maria Elena⁸^ORCID,Makepeace Benjamin L.⁹^ORCID,Gray Sean A.³,Carter Darrick³^ORCID,Lustigman Sara²,Abraham David¹^ORCID

Affiliation:

1. Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA

2. Laboratory of Molecular Parasitology, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA

3. PAI Life Sciences Inc., Seattle, WA 98102, USA

4. Vaxine Pty Ltd., Bedford Park, Adelaide, SA 5042, Australia

5. Alpha Genesis Inc., Yemassee, SC 29945, USA

6. IDEXX BioAnalytics, West Sacramento, CA 95605, USA

7. Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA

8. Texas Children’s Hospital Center for Vaccine Development, Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA

9. Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK

Abstract

Onchocerciasis remains a debilitating neglected tropical disease. Due to the many challenges of current control methods, an effective vaccine against the causative agent Onchocerca volvulus is urgently needed. Mice and cynomolgus macaque non-human primates (NHPs) were immunized with a vaccine consisting of a fusion of two O. volvulus protein antigens, Ov-103 and Ov-RAL-2 (Ov-FUS-1), and three different adjuvants: Advax-CpG, alum, and AlT4. All vaccine formulations induced high antigen-specific IgG titers in both mice and NHPs. Challenging mice with O. volvulus L3 contained within subcutaneous diffusion chambers demonstrated that Ov-FUS-1/Advax-CpG-immunized animals developed protective immunity, durable for at least 11 weeks. Passive transfer of sera, collected at several time points, from both mice and NHPs immunized with Ov-FUS-1/Advax-CpG transferred protection to naïve mice. These results demonstrate that Ov-FUS-1 with the adjuvant Advax-CpG induces durable protective immunity against O. volvulus in mice and NHPs that is mediated by vaccine-induced humoral factors.

Funder

National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/7/1212/pdf

Reference70 articles.

1. Melchers, N.V.S.V., Stolk, W.A., van Loon, W., Pedrique, B., Bakker, R., Murdoch, M.E., de Vlas, S.J., and Coffeng, L.E. (2021). The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030. PLoS Negl. Trop. Dis., 15.

2. Can ivermectin mass treatments eliminate onchocerciasis in Africa?;Winnen;Bull. World Health Organ.,2002

3. Senyonjo, L., Oye, J., Bakajika, D., Biholong, B., Tekle, A., Boakye, D., Schmidt, E., and Elhassan, E. (2016). Factors Associated with Ivermectin Non-Compliance and Its Potential Role in Sustaining Onchocerca volvulus Transmission in the West Region of Cameroon. PLoS Negl. Trop. Dis., 10.

4. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana;Awadzi;Ann. Trop. Med. Parasitol.,2004

5. Wanji, S., Eyong, E.-E.J., Tendongfor, N., Ngwa, C.J., Esuka, E.N., Kengne-Ouafo, A.J., Datchoua-Poutcheu, F.R., Enyong, P., Agnew, D., and Eversole, R.R. (2017). Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment. PLoS Negl. Trop. Dis., 11.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants;Vaccine;2023-11